Enroll the last patient in the COMPASS PWS Phase 3 study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 26 Feb 2025
- Due
- 31 Dec 2025
- Delivered
- Q2 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the last patient is expected to be enrolled in the fourth quarter of 2025”
What we found
Evidence strength B What the grades mean
Acadia's Q2 2025 results release says enrollment in the COMPASS PWS Phase 3 study was completed in the second quarter of 2025, before the Q4 2025 deadline. No exact completion day is given.
-
B Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
“As a result of favorable enrollment trends in the COMPASS PWS Phase 3 study of ACP-101 (intranasal carbetocin) in Prader Willi Syndrome, the Company now expects topline results from the study early in the fourth quarter of 2025.” ✓ confirmed on the page
-
B Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview
“Completed enrollment in the COMPASS PWS Phase 3 study of ACP-101 in the second quarter with top-line results expected early in the fourth quarter of 2025.” ✓ confirmed on the page
-
D Acadia's COMPASS PWS Study Fully Enrolled
“Acadia Pharmaceuticals has officially completed enrollment for its Phase 3 COMPASS PWS clinical trial of ACP-101 in individuals with Prader-Willi syndrome (PWS)—three months ahead of schedule!” not found on the page
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Enroll
- Deliverable
- COMPASS PWS Phase 3 study enrollment
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Acadia Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-ACAD-002591 · Corrections policy